News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Goutham Sunny Shares Phase I Data on Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1m and KMT2Ar AML
Goutham Sunny/LinkedIn
Jun 29, 2025, 09:27

Goutham Sunny Shares Phase I Data on Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1m and KMT2Ar AML

Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X:

“Phase I Study Update: Azacitidine + Venetoclax + Revumenib in older adults (≥60 yrs) with newly diagnosed AML harboring NPM1 mutations or KMT2A rearrangements
Revumenib (menin inhibitor) + azacitidine/venetoclax:
  • ORR: 88.4% (NPM1m: 85.3%, KMT2Ar: 100%)
  • CR/CRi: 81.4%, CR: 67.4%
  • Median time to response: 28 days; 84% responded in cycle 1
  • MRD-negative in all 37 assessed patients
  • Manageable safety: DS in 19%, QTc prolongation in 44% (no discontinuations)
Promising, targeted triplet combo for NPM1m/KMT2Ar AML.”

Title: Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Authors: Joshua F. Zeidner, Tara L. Lin, Rina Li Welkie, Emily Curran, Kristin Koenig, Wendy Stock, Yazan F. Madanat, Ronan Swords, Maria R. Baer, William Blum, Eytan M. Stein, Rebecca L. Olin, Gary Schiller, Angela Nichols, Olatoyosi Odenike, Elie Traer, Curtis Lachowiez, Vu H. Duong, Michael J. Hochman, Sheng F. Cai, Catherine Smith, Mona Stefanos, Molly Martycz, Ying Huang, Len Rosenberg, Sonja Marcus, Timothy L. Chen, Ashley O. Yocum, Brian J. Druker, Ross L. Levine, Uma Borate, John C. Byrd, Alice S. Mims

You can read the Full Article on Journal of Clinical Oncology

Goutham Sunny Shares Phase I Data on Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1m and KMT2Ar AML

More posts featuring Goutham Sunny.

 

Alice S. Mims AML Angela Nichols Ashley O. Yocum azacitidine Brian J. Druker cancer Catherine Smith Curtis Lachowiez Elie Traer Emily Curran Eytan M. Stein Gary Schiller Goutham Sunny John C. Byrd Joshua F. Zeidner Kristin Koenig Len Rosenberg Maria R. Baer Michael J. Hochman Molly Martycz Mona Stefanos Olatoyosi Odenike OncoDaily Oncology Rebecca L. Olin revumenib Rina Li Welkie Ronan Swords Ross L. Levine Sheng F Cai Sonja Marcus Tara L. Lin Timothy L. Chen Uma Borate venetoclax Vu H. Duong Wendy Stock William Blum Yazan F Madanat Ying Huang
Special Coverage
Blog
Jun 29, 2025, 09:27
Manchester Cancer Research Centre Shares Kathy Morse’s Story to Raise Awareness of Rare Gynecological Cancers
Science
Jun 29, 2025, 09:27
Goutham Sunny Shares Phase I Data on Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1m and KMT2Ar AML
Blog
Jun 29, 2025, 09:16
Chalothorn Wannaphut: Honored to Be The Top Winner in the Why I Research Challenge
Blog
Jun 29, 2025, 09:16
MASCC Wraps Up 2025 Meeting with Global Supportive Care Community
Blog
Jun 29, 2025, 09:09
Sahar Mansour Supports FUJIFILM Healthcare Middle East and Africa at Africa Health ExCon Conference 2025
Blog
Jun 29, 2025, 09:08
The PEACE-V STORM Trial Final Results Were Presented at ESTRO 2025
Blog
Jun 29, 2025, 09:07
Andreas Charalambous: Great to Meet with Lawson Eng at the MASCC2025
Blog
Jun 29, 2025, 09:00
Wafik El-Deiry Welcomes Dr. Sherise Chantell Rogers as Interim Associate Director for COE at Legorreta Cancer Center
Blog
Jun 29, 2025, 08:58
Toufic Kachaamy: What If You Want More Than What the Cancer Screening Guidelines Offer?
Insight
Jun 29, 2025, 08:11
Elena J. Ladas: Delighted to Share the Release of the IIPAN Manuals for the Delivery of Nutrition Care in LMICs
Blog
Jun 29, 2025, 07:54
Frank Sinicrope: FOLFOX + Atezolizumab is Now Incorporated Into The NCCN Guidelines for dMMR Colon Cancer
Science
Jun 29, 2025, 07:45
Yan Leyfman: Can a Digital Integrative Medicine Program Reduce Cancer-Related Fatigue?